{"entity":{"type":"insider","cik":"0001664251","url":"/insider/0001664251","json_url":"/insider/0001664251.json","name":"Barrowcliffe Susan E.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":9,"first":"2016-11-10","last":"2018-11-21","span_basis":"filed_date"},"name_variants":[{"name":"Barrowcliffe Susan E.","source":"filing","n_filings":9,"first_seen":"2016-11-10","last_seen":"2018-11-21"}],"transactions":[{"id":6283341,"accession":"0000899243-18-029542","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-029542","line_url":"/filing/0000899243-18-029542#line-2","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":30.04,"price_display":"30.04","price_state":"stated","total_value":1201600.0,"total_display":"1,201,600.00","total_whole":"1,201,600","shares_owned_after":9375.0,"shares_owned_after_display":"9,375","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-19","filed_date":"2018-11-21","scope":"insider"},{"id":6677455,"accession":"0000899243-18-000454","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000899243-18-000454","line_url":"/filing/0000899243-18-000454","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75000.0,"shares_display":"75,000","price_per_share":37.13586204533333,"price_display":"37.14","price_state":"stated","total_value":2785189.6534,"total_display":"2,785,189.65","total_whole":"2,785,190","shares_owned_after":25300.0,"shares_owned_after_display":"25,300","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-01-02","filed_date":"2018-01-04","scope":"insider","n_lines":6},{"id":4886758,"accession":"0000899243-17-022643","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-17-022643","line_url":"/filing/0000899243-17-022643#line-2","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":500000.0,"total_display":"500,000.00","total_whole":"500,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-25","filed_date":"2017-09-27","scope":"insider"},{"id":5282898,"accession":"0000899243-17-021595","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-17-021595","line_url":"/filing/0000899243-17-021595#line-4","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15167.0,"shares_display":"15,167","price_per_share":22.0023,"price_display":"22.00","price_state":"stated","total_value":333708.8841,"total_display":"333,708.88","total_whole":"333,709","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-06","filed_date":"2017-09-07","scope":"insider"},{"id":5282890,"accession":"0000899243-17-021595","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-17-021595","line_url":"/filing/0000899243-17-021595#line-2","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3223.0,"shares_display":"3,223","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":70906.0,"total_display":"70,906.00","total_whole":"70,906","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-05","filed_date":"2017-09-07","scope":"insider"},{"id":4927264,"accession":"0000899243-17-019355","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-17-019355","line_url":"/filing/0000899243-17-019355#line-2","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":11000.0,"total_display":"11,000.00","total_whole":"11,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-27","filed_date":"2017-07-31","scope":"insider"},{"id":4138643,"accession":"0000899243-17-018926","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-17-018926","line_url":"/filing/0000899243-17-018926#line-6","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4650.0,"shares_display":"4,650","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":102300.0,"total_display":"102,300.00","total_whole":"102,300","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-25","filed_date":"2017-07-25","scope":"insider"},{"id":4138639,"accession":"0000899243-17-018926","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-17-018926","line_url":"/filing/0000899243-17-018926#line-4","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":11000.0,"total_display":"11,000.00","total_whole":"11,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-24","filed_date":"2017-07-25","scope":"insider"},{"id":4138635,"accession":"0000899243-17-018926","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-17-018926","line_url":"/filing/0000899243-17-018926#line-2","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":960.0,"shares_display":"960","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":21120.0,"total_display":"21,120.00","total_whole":"21,120","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-21","filed_date":"2017-07-25","scope":"insider"},{"id":4691277,"accession":"0000899243-17-017958","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-17-017958","line_url":"/filing/0000899243-17-017958#line-2","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":20.2607,"price_display":"20.26","price_state":"stated","total_value":303910.5,"total_display":"303,910.50","total_whole":"303,911","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-03","filed_date":"2017-07-06","scope":"insider"},{"id":3354385,"accession":"0000899243-16-033508","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-033508","line_url":"/filing/0000899243-16-033508#line-2","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":500000.0,"total_display":"500,000.00","total_whole":"500,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-11","filed_date":"2016-11-15","scope":"insider"},{"id":2416899,"accession":"0000899243-16-033163","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-033163","line_url":"/filing/0000899243-16-033163#line-2","is_derivative":false,"issuer_cik":"0001631650","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001631650","owner_cik":"0001664251","owner_name":"Barrowcliffe Susan E.","owner_display_name":"Barrowcliffe Susan E.","owner_url":"/insider/0001664251","role":"Officer (General Manager, Europe)","role_mark":"O","role_mark_label":"Officer (General Manager, Europe)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Manager, Europe","security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":300000.0,"total_display":"300,000.00","total_whole":"300,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-08","filed_date":"2016-11-10","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":17,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":17,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":17},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001631650","name":"Aimmune Therapeutics, Inc.","url":"/issuer/0001631650","role":"Officer (General Manager, Europe)","n_filings":9,"first_seen":"2016-11-10","last_seen":"2018-11-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001664251","retrieved_at":"2026-08-27T06:19:53+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}